Heart failure performance measures

Eligibility and implementation in the community

Cecilia Berardi, Alanna Chamberlain, Francesca Bursi, Margaret May Redfield, Sheila M. McNallan, Susan A. Weston, Ruoxiang Jiang, Veronique Lee Roger

Research output: Contribution to journalArticle

Abstract

Background The goal of heart failure (HF) performance measures is to improve quality of care by assessing the implementation of guidelines in eligible patients. Little is known about the proportion of eligible patients and how performance measures are implemented in the community. Methods We determined the eligibility for and adherence to performance measures and β-blocker therapy in a community-based cohort of hospitalized HF patients from January 2005 to June 2011. Results All of the 465 HF inpatients (median age 76 years, 48% men) included in the study received an ejection fraction assessment. Only 164 had an ejection fraction <40% thus were candidates for β-blocker and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARB) therapy. Considering absolute contraindications, 99 patients were eligible to receive ACE inhibitors/ARB, and 162 to receive β-blockers. Among these, 85% received ACE inhibitors/ARBs and 91% received β-blockers. Among the 261 individuals with atrial fibrillation, 89 were eligible for warfarin and 54% received it. Of 52 current smokers, 69% received cessation counseling during hospitalization. Conclusion In the community, among eligible hospitalized HF patients, the implementation of performance measures can be improved. However, as most patients are not candidates for current performance measures, other approaches are needed to improve care and outcomes.

Original languageEnglish (US)
Pages (from-to)76-82
Number of pages7
JournalAmerican Heart Journal
Volume166
Issue number1
DOIs
StatePublished - Jul 2013

Fingerprint

Heart Failure
Angiotensin-Converting Enzyme Inhibitors
Angiotensin Receptor Antagonists
Quality of Health Care
Warfarin
Atrial Fibrillation
Counseling
Inpatients
Hospitalization
Guidelines
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Heart failure performance measures : Eligibility and implementation in the community. / Berardi, Cecilia; Chamberlain, Alanna; Bursi, Francesca; Redfield, Margaret May; McNallan, Sheila M.; Weston, Susan A.; Jiang, Ruoxiang; Roger, Veronique Lee.

In: American Heart Journal, Vol. 166, No. 1, 07.2013, p. 76-82.

Research output: Contribution to journalArticle

Berardi, Cecilia ; Chamberlain, Alanna ; Bursi, Francesca ; Redfield, Margaret May ; McNallan, Sheila M. ; Weston, Susan A. ; Jiang, Ruoxiang ; Roger, Veronique Lee. / Heart failure performance measures : Eligibility and implementation in the community. In: American Heart Journal. 2013 ; Vol. 166, No. 1. pp. 76-82.
@article{68b7c8cfe3784e6ab0e34f444e2adb17,
title = "Heart failure performance measures: Eligibility and implementation in the community",
abstract = "Background The goal of heart failure (HF) performance measures is to improve quality of care by assessing the implementation of guidelines in eligible patients. Little is known about the proportion of eligible patients and how performance measures are implemented in the community. Methods We determined the eligibility for and adherence to performance measures and β-blocker therapy in a community-based cohort of hospitalized HF patients from January 2005 to June 2011. Results All of the 465 HF inpatients (median age 76 years, 48{\%} men) included in the study received an ejection fraction assessment. Only 164 had an ejection fraction <40{\%} thus were candidates for β-blocker and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARB) therapy. Considering absolute contraindications, 99 patients were eligible to receive ACE inhibitors/ARB, and 162 to receive β-blockers. Among these, 85{\%} received ACE inhibitors/ARBs and 91{\%} received β-blockers. Among the 261 individuals with atrial fibrillation, 89 were eligible for warfarin and 54{\%} received it. Of 52 current smokers, 69{\%} received cessation counseling during hospitalization. Conclusion In the community, among eligible hospitalized HF patients, the implementation of performance measures can be improved. However, as most patients are not candidates for current performance measures, other approaches are needed to improve care and outcomes.",
author = "Cecilia Berardi and Alanna Chamberlain and Francesca Bursi and Redfield, {Margaret May} and McNallan, {Sheila M.} and Weston, {Susan A.} and Ruoxiang Jiang and Roger, {Veronique Lee}",
year = "2013",
month = "7",
doi = "10.1016/j.ahj.2013.03.008",
language = "English (US)",
volume = "166",
pages = "76--82",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Heart failure performance measures

T2 - Eligibility and implementation in the community

AU - Berardi, Cecilia

AU - Chamberlain, Alanna

AU - Bursi, Francesca

AU - Redfield, Margaret May

AU - McNallan, Sheila M.

AU - Weston, Susan A.

AU - Jiang, Ruoxiang

AU - Roger, Veronique Lee

PY - 2013/7

Y1 - 2013/7

N2 - Background The goal of heart failure (HF) performance measures is to improve quality of care by assessing the implementation of guidelines in eligible patients. Little is known about the proportion of eligible patients and how performance measures are implemented in the community. Methods We determined the eligibility for and adherence to performance measures and β-blocker therapy in a community-based cohort of hospitalized HF patients from January 2005 to June 2011. Results All of the 465 HF inpatients (median age 76 years, 48% men) included in the study received an ejection fraction assessment. Only 164 had an ejection fraction <40% thus were candidates for β-blocker and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARB) therapy. Considering absolute contraindications, 99 patients were eligible to receive ACE inhibitors/ARB, and 162 to receive β-blockers. Among these, 85% received ACE inhibitors/ARBs and 91% received β-blockers. Among the 261 individuals with atrial fibrillation, 89 were eligible for warfarin and 54% received it. Of 52 current smokers, 69% received cessation counseling during hospitalization. Conclusion In the community, among eligible hospitalized HF patients, the implementation of performance measures can be improved. However, as most patients are not candidates for current performance measures, other approaches are needed to improve care and outcomes.

AB - Background The goal of heart failure (HF) performance measures is to improve quality of care by assessing the implementation of guidelines in eligible patients. Little is known about the proportion of eligible patients and how performance measures are implemented in the community. Methods We determined the eligibility for and adherence to performance measures and β-blocker therapy in a community-based cohort of hospitalized HF patients from January 2005 to June 2011. Results All of the 465 HF inpatients (median age 76 years, 48% men) included in the study received an ejection fraction assessment. Only 164 had an ejection fraction <40% thus were candidates for β-blocker and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARB) therapy. Considering absolute contraindications, 99 patients were eligible to receive ACE inhibitors/ARB, and 162 to receive β-blockers. Among these, 85% received ACE inhibitors/ARBs and 91% received β-blockers. Among the 261 individuals with atrial fibrillation, 89 were eligible for warfarin and 54% received it. Of 52 current smokers, 69% received cessation counseling during hospitalization. Conclusion In the community, among eligible hospitalized HF patients, the implementation of performance measures can be improved. However, as most patients are not candidates for current performance measures, other approaches are needed to improve care and outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84879784200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879784200&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2013.03.008

DO - 10.1016/j.ahj.2013.03.008

M3 - Article

VL - 166

SP - 76

EP - 82

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -